GSK's Hal Barron On R&D Progress At Two-Year Mark
R&D Chief Says Doubters Are Coming Round
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
You may also be interested in...
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.